Перейти к содержимому

amandahao

Members
  • Публикации

    40
  • Зарегистрирован

  • Посещение

Репутация

0 Neutral

О amandahao

  • Звание
    Любопытный

Previous Fields

  • Обращение
    на "Ты"
  1. Ddu, the leading global pharmaceutical & medical device products B2B online platform, is currently attending global exhibitions, leaving its footprints at multiple word-class medical trade shows in South Korea, India, Chongqing (China), Turkey and the United States. I. Korea KIMES Time: March 15th - 18th Location: Seoul, Korea The 34th (KIMES 2018) is Korea's largest medical exhibition for medical and hospital equipment, covering medical devices, diagnostic imaging equipment and medical aids. With a market size of more than 10 billion USD, there is huge potential and broad prospects for market development in the Korean pharmaceutical industry. This was the second time Ddu had attended KIMES in Korea, and the Internet + cross-border medical trade model was widely received with praise by Korean medical traders. II. India Medical Fair Time: March 16th - 18th Location: Mumbai, India Ddu attended the Medical Fair India 2018 with products of priority members and attracted numerous visitors. The exhibition is a professional trade show for Indian hospitals, medical devices and equipment and is one of the most famous exhibitions of the medical industry in South and Central Asia. III. CACLP China Time: March 17th - 19th Location: Chongqing, China The 15th China Association of Clinical Laboratory Practice Expo (CACLP Spring Meeting), founded in 1991, is the most professional and influential medical exhibition in China with the largest number of attendees. IV. Expomed Turkey Time: March 22th - 25th Location: Istanbul, Turkey The 25th Expomed is a pioneering medical exhibition in Europe and Asia with an exhibition hall that covers an area of 32,000m² and contains 7 exhibition halls. Many a local exhibitor in Turkey showed great interest in Ddu's Internet-based transaction model and, after consulting with Ddu staff, found it a practical and user-friendly platform. V. Next destinations: Singapore, Shanghai (China), the United States Ddu has committed to not only exploring oversea markets, but to also gain more business deals for users on the platform. Ddu is going to attend MEDLAB in Singapore, CMEF in Shanghai and CPhI in the United States. Source:https://medicaldevicesblog.tumblr.com/post/173058682970/drugducom-international-medical-exhibition
  2. According to the latest data, the population of the Philippines has exceeded 100 million, and the demand for various types of medicine shows a steady increase. With the advancement of relations between China and the Philippines and collaborations in economy and trade, the Philippines has become a prime exporting country for Chinese pharmaceutical companies. Before you can become eligible to set foot in the Filipino market, you have to become GMP certified for pharmaceutical drugs. Ddu, the leading global pharmaceutical & medical device products B2B online platform, will share some insight we have gained on the process of GMP certification for pharmaceutical drugs in the Philippines. (Keep in mind that the Philippines is a member of ASEAN but not of PIC/S). Here follows an outline of the procedures for GMP certification of pharmaceutical drugs in the Philippines. The documents needed for FDA certification in the Philippines are as follows: In addition to this, overseas production companies applying for GMP certification in the Philippines are required to perform inspections unless the documents submitted for GMP certification are deemed to be absolutely complete. If the production company has a GMP certificate from a PIC/S member country or WHO prequalification, they can also apply for exemption from factory inspection. This does however depend on the characteristics of the specific product and the integrity of the documents. The time for overseas inspections is decided by the number of auditing officials and their workload. The Philippine FDA usually accumulates a large number of applications for overseas inspections in order to perform inspections on multiple factories in the same area. Normally, a GMP audit for a production company includes document reviews and on-site inspections for production, which takes approximately three days and is conducted by two to three officials. (Reference standard: GMP requirements for PIC/S members). If the APIs and the drugs are produced separately in different plants, both will be subject to inspection, thus the time will be extended accordingly. Ddu, the leading global pharmaceutical & medical device products B2B online platform, has learnt that the Philippine FDA resumed overseas inspections in May 2017 after they were suspended in November 2016. Currently only inspections of oral formulations are available and applications for inspection of products with recertification will be given priority. Moreover, inspection of injections of biological agents (including vaccines) are on the way. Source:http://forums.delphiforums.com/medicaldevice/messages/41/1
  3. What to do if you are rejected by your client

    Lydia’s client made himself clear that he was not interested in her products and ask her not to contact him again after she had followed up on him for several days. If you are in sales, you have probably encountered this all-too-familiar situation of being rejected without any clear reasons, but it’s necessary to keep in touch with your clients and wait for another opportunity. So what would your options be to remedy the situation? First of all, figure out why your clients turn you down. I. Does the client have any current purchasing requirements? Very few clients can place orders 24/7, especially in the international B2B trade. Generally, a client may place several order in a year, only when it is necessary. II. Your client is not looking for another medical device supplier If your client is satisfied with their current supplier and benefiting from being with them, it is unlikely that they would switch to a new supplier. III. Your company doesn’t offer any special advantages compared to the current medical device supplier. In the event that you connect with a potential client in the process of looking for a new supplier, your company needs to make the move worth their while. There are always risks involved in making a change such as this so be sure to offer them something competitive. IV. Is the client part of your target market? Clients may have requirements outside of what you can offer them. Recommending them to the right suppliers and keeping ties with them is, however, always a good idea. It often happens that they either recommend you to others or turn to your company when the time is right. So what should you do when you are turned down by your client? I. Before you follow up on your client, find out whether there are any possibilities for a collaboration and make sure they are part of your target market. II. Determine whether the client has any immediate purchasing requirements and don’t waste your (and their) time by bombarding them with follow-up calls if they don’t. III. Don’t get discouraged. After being rejected, re-assess the situation and come back with a new strategy. IV. Always establish a fail-safe in advance when dealing with clients and handle emergencies smartly. V. Provide your client with more payment methods at discretion. For example, if your competitors all offer letter of credit at sight, give your client the option of a usanceletter of credit. Being in sales requires determination and grit, so stay focused and don’t lose heart. Know your product well and know your competitors. Also keep yourself updated with the lasted demands and .s. When you do meet rejections, find out what the reason for it , this way you can accumulate knowledge and better strategize for the future. Source:https://medicaldeviceandequipmentinformation.wordpress.com/2018/04/18/what-to-do-if-you-are-rejected-by-your-client/
  4. Three ways you can act to reduce the risk

    If 2017 was about ransomware attacks, 2018 will be about cyber attacks on the Internet of Things( medical device products). As we begin the year, that’s the message we’re hearing from a number of sources. This should come as no surprise to those of us in the **healthcare** industry, given the recent attention on devices such as pacemakers, which were the focus of an **FDA** recall last year. Device security is a complex problem, partly because there is no industry-standard operating system for products such as insulin pumps, CT scanners, pacemakers, and the like. Many devices use “off-the-shelf” software that’s vulnerable to viruses and worms, according to the U.S. FDA . What’s worse, a small percentage of older devices run on operating systems like Windows XP that no longer receive security updates. And countless devices built 20 years ago or more—when Windows 95 was considered the latest in technology—are still in service to- So what exactly can be done to secure these important, life-critical devices? Surprisingly, the answer doesn’t lie exclusively in the IT/security department (although technology plays a large part, to be sure). Forming a holistic, effective device security strategy means addressing three major areas of focus: Organizational. Take a look at your structure: Are teams working together effectively with a shared goal in mind? Does Information Security** tend to restrict access because they are trying to protect medical records, while Information Technology has a bias toward functionality and uptime? Do biomedical medical device products technicians have exposure to security personnel who can help them understand the complexities at play? Small shifts in organizational structure can have a big impact when it comes to security. Process. You have a plan for natural disasters, mass casualty events, and other emergencies. But have you outlined the process for what to do in the event of a device security breach? How would you know if a breach happened? Other areas to look at might include your culture (Do clinicians engage in risky behavior? Are you making security easy and hassle-free for them?) and/or your process for procuring new devices. Technology. Yes, as mentioned, technology is key—and worthy of investment. From simply keeping up with patches to micro-segmenting your devices to replacing your entire network, there are a number of technology solutions you can employ to ensure your devices stay secure and patients (and their data) are protected. Source: https://medicalnews.quora.com/Three-ways-you-can-act-to-reduce-the-risk
  5. 4 Ways to Find Medical Device Buyers in 2018

    Those who are engaged in foreign trade have undoubtedly realized that it is getting trickier to secure reliable customers even though they send thousands of development letters to find medical device buyers. So, with increasing competition, how is it possible to obtain more target clients? In the long run, improving product competitiveness and branding may look like the choice we will take, but what are the most efficient short term methods of customer development? Ddu (www.drugdu.com), the leading global pharmaceutical & medical device B2B online platform, will share 4 tricks for customer development with examples of medical devices that, in our experience, have led to good results. I. Catalogue of exhibitors Every year, there are various medical equipment exhibitions where people are able to communicate face-to-face with clients. However, not every company can afford to attend exhibitions, which is why exhibitor catalogues are very useful. On the official website of an exhibition there is usually a catalogue of exhibitors where you can search for information such as websites and emails of medical device buyers. II. Search engines On a medical device company’s official website, you will be able to find their email address under “Contact us”. Take “www.abc.com/contactus.html” for example, simply input key words such as “products+inurl:contactus” on the website and you will directly go to “Contact us”. If, for example, you input “hospital bed buyer inurl:contactus” in Google, you will get the results of the “Contact us” pages of hospital bed buyers’ websites. III. Yellow pages websites Most medical device companies in Europe link their official websites to the yellow pages. This is a simple way of collecting the contact information of your potential clients allowing you to send them development letters. IV. B2B platforms B2B platforms are the most frequently used and easiest way to develop new clients. It does, however, take more than simply uploading the products if you want it to work for you since keyword optimization plays a major role in making your products searchable. In order to optimize your use of B2B sites, first start by applying the following formula: “product name + parameter (function, color, size, texture etc.) + keyword/category + model number” and keep it to more or less 60 characters. Secondly, different products of the same type should be described from multiple perspectives to avoid repetition of the various keywords used for searching. Make use of Google AdWords (https://adwords.google.com/intl/en_hk/home/tools/keyword-planner/) to find the most frequently used search words for your products. It is also very useful and effective to use different keyword when editing product titles. Thirdly, make use of alternative opportunities by keeping an eye on the promotional activities hosted by the B2B platform. Ddu(www.drugdu.com), a B2B platform focused on the medical industry, is currently hosting an online recruitment rally for medical devices which is done by collaborating with global social media giants like Google, Facebook, Yahoo and LinkedIn. During the online rally, Ddu will select dozens of priority products to conduct online promotions, helping users to get maximum exposure for their products and locate potential business partners. A former participant of the online hospital bed exhibition stated that he received over 10 inquires during the Chinese Spring Festival (February 2018) which is why Ddu is currently has another online recruitment rally for 14 medical devices in full swing. Register on Ddu and complete your product information to join in the activity for free! Since Ddu is currently hosting a promotion, you can register online before March 31st. Not only can you apply for the online recruitment rally, but you also stand the chance to have your products increase in rank and be first on the list! Link for application of the online recruitment rally: http://act.drugdu.com/2018-Online-Exhibition-Medical-Device-Products-Recruitment-969490005165211648.html
  6. POLICY CHANGE! Only 35 Days for New Drug Approvals!

    Beijing Beishengyan biological Product’s Sabin Strain Inactivated PolioviursVaccine (Sabin IPV), secured approval from the China Food and Drug Administration (CFDA) in August 2017. On September 29th, Sabin IPV was officially on the market, offering one more option for IPV precaution. With the exception of time for material supplements, the CFDA took only 35 days to process production, registration and application of Beishengyan’s IPV and issue a drug approval number and certificate. Ddu, the leading global pharmaceutical & medical device products B2B online platform, learned that it usually takes 150 days to complete all the processes. This begs the question: how did Beishengyan do it within 35 days? It turns out that the “special review and approval procedure” did it a favor! The special review and approval procedure for drug registration refers to the procedure and requirements of the State Food and Drug Administration to carry out special review and approval of drugs for handling public heath emergencies under the principle of unified leadership, early involvement, expeditiousness and efficiency, and scientific review and approval, in an effort to approve drugs for the prevention and treatment of public health emergencies as soon as possible under the threat or after the occurrence of public heath emergencies. So what are the requirements of the special review and approval procedure? 1. What types of drugs fall under the special approval category? A. According to Decree no. 17 of the China Food and Drug Administration, the following drugs are entitled to the special review and approval procedure. The State Food and Drug Administration may, according to law, decide to follow the Procedure to conduct special review and approval of drugs for public health emergencies in any of the following circumstances: (1) Where the President of the People’s Republic of China declares a state of emergency or the State Council decides that certain areas within a province, autonomous region or municipality directly under the Central Government are in a state of emergency; (2) Where the contingency program for public health emergencies is initiated according to law; (3) Where the drug reserve department or the health administrative department of the State Council proposes a special review and approval for drugs having existing national drug standard; (4) Other circumstances applicable to special review and approval. B. According to Decree no. 17 of the China Food and Drug Administration, the State Food and Drug Administration is responsible for the review and approval of clinical trials, production and importation of drugs for the prevention and treatment of public health emergencies. The (food and) drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall, upon entrustment of the State Food and Drug Administration, be responsible for on-site inspection and sampling of the pilot products of the drugs for the prevention and treatment of public health emergencies. Beishengyan’s Sabin IPV happened to meet all the requirement of drugs for the prevention and treatment of public health emergencies. 2. What are the processes of the special review and approval procedure? 1) Submission of application Drugs which fall under categories 1 and 2 must apply for the special review and approval procedure when they apply for clinical trials. Drugs which fall under categories 3 and 4 must apply for the special review and approval procedure during the same time period as applying for production. 2) Summit documents Both the Special Review and Approval Procedure form and other relevant documents should be submitted to the department of drug registration. After this has been done, the documents must be submitted to the center of drug approval at the CFDA. 3. Time of review Special review and approval procedure for categories 1 and 2 should be done within 5 days, and categories 3 and 4 within 20days. 4. Supplementary documentation The CFDA will assign an expert group to evaluate and review the registration application and, if supplementary documents are needed, applicants must submit the documents as required within 20 days. 5. Communication If problems concerning safety or clinical trials schemes are encountered during the process, applicants can summit the Special Review and Approval Procedure Communication form and relevant documents for further discussion. 6. Issuing of certificates Where the State Food and Drug Administration decides to approve the drug, it shall issue the Letter of Approval for Drug Registration, and may grant an approval number for the drug at the same time if the applicant has appropriate manufacturing conditions; if it decides to disapprove the manufacturing, it shall issue a Disapproval Notice with reasons. In the event that your company has drugs that meet the requirements above, act right now and hope you can also get them registered within only 35 days! For more information, please visit 滴度中文资讯频道 - 滴度中文资讯频道
  7. In collaboration with Google, Facebook, Yahoo and LinkedIn, Ddu recently launched their priority products rally to help users on the platform capture business opportunities, hosting an online medical device product fair to get mass exposure for users' quality products. Recruitment Click the image above to register During February 2018, the first round kicked off with 25 medical nursing beds and products taking part in the rally. They received 532 inquiries and over 1,550,000 impressions. This was done using comprehensive promotions and multiple EDM channels, banner promotions on the Ddu homepage, media and soft text advertising and designated spaces for priority products. Real data of inquiries during the Ddu online rally Examples of medical nursing bed promotions Ddu is currently hosting another online recruitment rally for the following 14 medical device products! Join us not to miss out on this great opportunity! You’re only three steps away from promotional benefits worth millions of dollars! Step 1 - Register on Ddu Step 2 - Complete your information on the company page and of your products, Step 3 - Apply for the Ddu online medical device product fair! Link for application: http://act.drugdu.com/2018-Online-Exhibition-Medical-Device-Products-Recruitment-969490005165211648.html Tip: By recommending the online rally to others, your product will increase in rank and be first on the list! Source: https://wordpress.com/post/medicaldeviceandequipmentinformation.wordpress.com/118
  8. For pharmaceutical companies who want to explore international markets, identifying these target markets is the first step. Being able to pinpoint the right target market, will increase the probability for more business deals. In order to help you with this process, we have listed 5 of the more important aspects to consider. I. Product information A. Know your products Pharmaceutical drugs are different from other general products since their quality has a great impact on treatments. This, of course, is why there are strict management standards for drugs in every country. Before any drug is released onto the market, it must be registered and approved by the local drug regulators. Therefore, you should familiarize yourself with all of the drug’s relevant information like registrations, classifications, clinical and non-clinical trials. B. Know your competitors Gather as much information about domestic exporters of the same products in terms of registration information, workshop production lines and GMP certifications to identify your competitive advantages. II. Product market sales A. Domestic competitors Do research on the countries your competitors export their products to. In general, the countries that your products can enter should be your priority market and the ones with large sales volumes should be the focus of your future developments. B. Branded drugs If there are no domestic companies exporting their products to your target market, it’s advisable for you to research the sales of branded drugs in international markets and decide on your next move from there. C. Market capacity If you have limited access to the above information, identifying the potential market capacity can also serve your purposes. Usually, the local population and the corresponding incidence of diseases can be used as a reference. III. Retail price After identifying the target countries, the next step is to assess the price of the drugs in the target markets and the estimated profits. Tip: The local retail price of the drugs and the CIF import price of the products sold, should also be taken into consideration. IV. Registration requirements of target countries While fully investigating the market, you also need to carefully review the registration laws and regulations for drugs in the target countries and scrutinize the following key points: a. Requirements for GMP certification; b. Requirements for clinical and non-clinical data; c. Whether there is a need for clinical trials in the target country; d. Whether the drug regulatory authorities in the target country need to conduct an on-site inspection of the drug's production line? e. Development planning Your market development plan has to be in line with the company's short, medium and long-term planning. In general, countries with a large market capacity and very strict regulation laws may serve as long-term development goals while countries with low registration requirements and no on-site inspections for clinical trials and production could be short-term targets, allowing you to get your products registered as soon as possible. After analyzing the factors mentioned above, you should be better equipped to make more informed decisions regarding the possibilities of exploring your target markets, enabling you to make reasonable plans for the ones you wish to develop. Source: https://medicaldeviceproducts.quora.com/Five-tips-for-exploring-pharmaceutical-drug-export-markets
  9. The Arab Health Exhibition 2018 was successfully held at the Dubai International Convention & Exhibition Centre from January 29th to February 1st, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, attended the exhibition along with three priority members, taking home valuable resources. As the largest international and professional exhibition in the Middle East, Arab Health is well-known to hospitals and medical device and products agents in Arab countries. According to statistics, this exhibition attracted more than 4,200 medical device exhibitors and over 103,000 professional attendees from an estimated 150 countries. During the exhibition, Wenzhou HaiRou I/E Co., Ltd., Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and GETT Asia Ltd., attended through Ddu’s joint-exhibition program and enjoyed online and offline business matching services. Visitors were able to experience the service by scanning a QR code, posting RFQs and then receive the matching results from the platform. Shenzhen Tianlang Medical Equipment Co., LTD, a supplier of disposable anesthesia laryngoscope, reusable video laryngoscope (split type) and endoscopic video system, promoted its disposable anesthetic laryngoscope on Ddu’s front page, claiming that they had been members of Ddu for 6 months and during that time they received over 40 RFQs and that they were excited about future prospects. According to the management of Ddu, for buyers and suppliers to save more time and cost spent in search of new international clients, Ddu is utilizing innovative technologies such as scanning QR codes and posting RFQs to help shorten the time periods searching and to boost more orders. Ddu attends dozens of exhibitions every year with great investments in manpower and resources and is committed to providing intimate services for promotions and customer services for priority members. GETT Asia, a professional supplier of medical keyboards and mice, is a priority member of Ddu. In an interview with Ddu they stated that “Our business in Asia is going strong, we hope Ddu can help us find more new clients and attend more international exhibitions.” According to Ddu management, the company is going attend over 30 exhibitions and boost more business deals for users on the platform. If you intend to explore international market, join Ddu to enjoy online and offline global promotion services! Official website : DrugDu- Leading Global Pharmaceutical & Medical Device Platform Hotline:400-106-9990, Tony, sales manager E-mail:business@drugdu.com Source:https://dduamanda.wixsite.com/medicalnews/single-post/2018/03/05/Ddu-Attended-Arab-Health-A-Perfect-Match-for-International-Trade
  10. Choices for Your Ideal Medical Hospital Beds

    Nursing facilities and home- and community-based services are important for individuals' well-being and can often prevent the need for acute inpatient hospitalizations, which is why it’s important to choose suitable medical hospital beds. Ddu, the leading global pharmaceutical & medical device B2B online platform, now offers you some suggestions on how to choose your medical hospital beds. 1. Safety of medical hospital beds Nursing beds are designed for patients with mobility difficulties and who are sick abed, placing higher demands on the safety and stability of care beds. So when choosing nursing beds, it's necessary to check the registration certificate of medical products and production license of the suppliers. Below is a selection of 25 nursing beds on Drugdu.com with CE or ISO certification, click the link for more details: http://act.drugdu.com/Hospital-Beds-B-959283668972437504.html 2. Manual or electrichospital beds Manual hospital beds are for short-term care of patients while electrical ones are for patients with mobility difficulties and who are sick abed. With the aid of these medical hospital beds, patients are able to move freely, which is conducive to their rehabilitation. Moreover, electric medical beds are much more user-friendly than the manual models but prices are also higher than that of manual ones. 3. Motor-driven ICU hospital beds These beds are suitable for patients with little independent activity, who have gone through the early and dangerous stages of a serious paralysis condition and are hospitalized at clinics with limited nursing staff. These beds are used to effectively prevent major complications (pneumonia, urinary tract infections and bedsores) in patients. 4. Collapsible medical hospital beds This type of nursing bed is suitable for patients who are recovering from fractures, for the health care of long-term bedridden patients, for patients with specific sleeping needs, learning, entertainment and other needs. There is a great variety of medical hospital beds with a wide range of functions and purposes, specific to every patient’s needs. Taking time to do some research on product sales, certification, functions and other aspects before making a deal is highly advisable. Speaking to professionals is another way of ensuring you get the best hospital bed equipment, so feel free to speak to our specialists at Drugdu.com. Source:http://forums.delphiforums.com/medicaldevice/messages/36/1
  11. The First Choice for 500,000+ People Engaged in the Medical Industry Ddu (www.drugdu.com) is the world's first B2B online platform focused on the cross-border trade of pharmaceuticals and medical devices. As a pioneer in the industry, Ddu is committed to accelerating the circulation of the pharmaceutical and medical device trade around the world, making it simpler, easier and more efficient. It is a well-known fact that there is a constant demand for pharmaceuticals and medical device products in the health care industry and with the development of an aging society, cross-border medical trade is on the increase with an overall growth rate of 15% every year. However, there are numerous problems such as the difficulties of finding buyers as well as cross-border trade and communication issues in the industry. Moreover, getting in touch with new clients by attending countless exhibitions remains to be an issue and is often completely fruitless. With advanced technology and expertise in the international medical trade industry, Ddu has provided a full range of solutions for thousands of global suppliers and buyers to build and develop channels of communication and expand oversea international business opportunities. Attracting over 100,000 companies from more than 100 countries with up to 1,000,000 pieces of product information, the platform allows you to view pharmaceuticals and medical device products, information of suppliers and trade history with the simple click of a button. Specialized customer service also goes hand in hand with the platform, breaking information barriers in medical trade by recommending potential partners and products to users. This is done by displaying products, supply and demand information and big data intelligent matching. Brand promotion services like the Ddu Credit Verification, the Ddu Trade Accelerator and the Ddu Global Promotion plan with mature methods and efficient promotional channels, offer you great opportunities for brand and product exposure. 1. Credit Verification The Credit Verification service aims to serve cross-border trading companies by offering objective, strict and detailed verification services on basic information and qualifications which is intended to help users build brand integrity, promote core competencies and increase exposures of brands and products in global markets. 2. Trade Accelerator A one-stop online promotion service, aimed to help pharmaceutical and medical device companies get effective enquiries and swiftly develop global targeted markets, providing you with market strategies, global promotional channels, enterprise page designs and a credit verification guarantee. 3. Global Promotion Plan Since the launch of the Ddu Global Promotion Plan, Ddu has succeeded in helping users do international product promotions from the comfort of their own homes as well as match thousands of orders, thereby rapidly gaining popularity in the medical trade industry. Based on global exhibitions and online/offline comprehensive promotions, Ddu is committed to accelerating market development and product and brand internationalization for medical enterprises. Visit www.drugdu.com for more details on how to register as a pharmaceutical and medical device supplier and connect with more buyers to expand your marketing scope. Register as a Drugdu.com supplier to promote your products and expand your marketing scope, click here. Register as a Drugdu.com buyer to find reliable suppliers and quality products, click here. For business marketing and enquiries please email marketing@drugdu.com or call +86 400-106-9990. Source:https://medicaldeviceandequipmentinformation.wordpress.com/2018/02/11/ddu-professional-platform-for-cross-border-medical-trade/ see more at www.drugdu.com
  12. Medical Device products Market in Malysia

    Malaysia represents one of the most vigorous and vibrant medical device products markets in Southeast Asia, presenting opportunities for U.S. exporters of medical technology to expand their sales into rising economies. Increasing patient access to healthcare will remain in the focus of the Government of Malaysia for the next five years, to include upgrading facilities and equipment, and expanding delivery systems. Malaysia’s national healthcare expenditure historically is around 4 to 5 percent of GDP. In 2014, the Malaysian government set aside approximately $5.83 billion, or 8.4 percent of the yearly national budget, for public healthcare. Out of this allocation, 7.5 percent is assigned for development purposes. Comparing public and private hospital expenditure, the public hospitals expenditure is about 65 percent while the private sector is around 35 percent. The number of hospital beds for both public and private healthcare combined has increased from 55,180 in 2010 to 58,530 in 2014. Public hospital beds accounted for 75 percent of total hospital beds in 2014. Total two-way trade for Malaysia’s medical device industry for 2014 is $1.98 billion. Malaysian imports of medical, surgical, dental and veterinary science instruments and devices amounted to $735 million. Singapore (27 percent) is the highest supplier to Malaysia. This is followed by the United States (19 percent), Germany (13 percent), Japan (8 percent), China (7 percent) and South Korea (3 percent). Overall, Malaysian medical device imports increased 8 percent over 2013. It is also worthwhile to note that Singapore is a major trans-shipment point for the Association of South East Asian Nations (ASEAN) region. Exports for the same category of medical instruments and devices from Malaysia increased 24 percent to $1.24 billion in 2014. Top export destinations for Malaysia in this sector are the United States (43 percent), Germany (14 percent), Japan (22 percent) and Singapore (12 percent). It is also interesting to note a marked increase in total trade between Malaysia and the Netherlands. Total bilateral trade between Malaysia and Netherlands is $60 million for 2014, a 143 percent increase since 2013. The Government of Malaysia designated the Medical Device Industries sector as high growth potential in its next five year strategic economic plan (2016–20), also known as the 11th Malaysian Plan. According to the Malaysian Ministry of International Trade and Industry, from 2010 to 2014, foreign medical device industry investments into Malaysia totaled MYR 11 billion ($2.9 billion) while domestic investments were MYR 1.2 billion ($316 million). Improving and achieving universal access to quality healthcare will be the focus of the Malaysian government for the next five years. The major thrusts will be in improving healthcare quality to underserved populations, as well as ensuring efficient and effective expansion of the healthcare delivery system. In addition to upgrading healthcare facilities, a government priority is to reduce communicable and non-communicable diseases (CD and NCD). E-Health Information and Communications Technology (ICT) strategy will be implemented concurrently to track and support these measures. Market Entry Many exporters designate a Malaysian-based trading company as their local sales agent responsible for handling customs clearance of imported goods, for dealing with established wholesalers and/or retailers, for marketing the product directly to major corporations or the government and for handling after-sales service. In some cases, especially when selling to the government, a Malaysian Bumiputra status distributor is required. The term Bumiputra refers to a Malaysian of Malay or indigenous racial origin. The passing of Act 737 and Medical Device Regulations 2012 has changed the regulatory framework for Malaysia. Industry players intending to export to Malaysia now need to register their medical device products with the Malaysian Medical Device Authority. Pharmaceutical and health supplements registration is with the National Pharmaceutical Control Bureau. Current Market .s Increasingly, more Malaysians are taking the approach of wellness and disease prevention rather than treatment. Food and vitamin supplements are seen as preventive measures towards maintaining optimal health. Basic vitamin and pro-vitamins, as well as natural and organic supplements, are gaining popularity. The United States is the largest supplier of healthcare supplements to Malaysia. U.S. brands are both trusted and well received by local consumers. As for dental market .s, we are seeing subspecialties in the area of orthodontics, implant and esthetic procedures increasingly being offered in private dental clinics. The United States is one of the leading suppliers of orthodontics products in Malaysia. Private healthcare services in Malaysia are predominantly used by the upper-middle to affluent segment of the population. As per capita GDP rises, demand for private healthcare consumption is expected to increase in tandem. Health screening is increasingly popular. Medical aesthetics procedures are also gaining ground in Malaysia. Similar to other increasingly affluent countries, noncommunicable diseases, such as diabetes, highblood pressure, cardiovascular disease, oncology cases and obesity, are on the rise in Malaysia. Main Competitors The main competitors for U.S. companies in the Malaysian market are from the EU countries of Germany, the Netherlands, United Kingdom and France. Japan, China and South Korea have a strong presence in the Malaysian market as well. As noted above, statistical data show that the Netherlands made strong inroads into the Malaysian market in 2014 for the medical device sector with 143 percent total bilateral trade growth over 2013. Current Demand Consolidation is the key word for public healthcare resources and facilities. The Malaysian government is taking steps to implement a hospital cluster concept in select locations. Hospitals within a similar geographic region will serve as one unit sharing assets, amenities and human resources. Additionally, existing healthcare facilities and assets will also be upgraded. Healthcare services to the rural and remote areas will be expanded via mobile healthcare teams and flying doctor services. Implementation of the e-Health strategy will include incorporating existing information and communications systems into one system-wide module. This should improve health data management and support research and development and commercialization initiatives. Pre-hospital care, such as ambulance services and accidents/emergencies services, will also be a key focal area. Ideally, collaboration between private sector and non-governmental (NGO) ambulance service providers will improve response time and better resource utilization. Demand for private healthcare has been increasing exponentially due to its speedy service delivery and quality healthcare. In 2013, private hospital outpatient attendance was 6.8 percent of overall outpatient care provided in-country. Private hospitals also command 32.2 percent of total hospital admissions. In 2013, approximately 25 percent of the doctors, 38 percent of dentists and 33 percent of pharmacists were in private practice. Registration Process The Malaysian Medical Device Act (Act 737) took effect in 2012. Related Regulations specify requirements and procedures to medical device registration, conformity assessment body (CAB) registration, establishment licensing, export permit and appeal. The Regulations went into force on July 1, 2013. A transition period of two years for medical device registration and one year for establishment licensing was given to the industry before the Regulations were fully enforced. The Medical Device products (Exemption) Order 2015 has extended the transition period of medical devices registration for another year, ending June 30, 2016. Thereafter, all medical device manufacturers in Malaysia will need to register their medical devices with the Medical Device Authority. Importers and distributors will also need to obtain an establishment license to import and distribute medical devices locally in Malaysia. Barriers All foreign companies need to work with a Malaysian company that is registered with the Malaysian Ministry of Finance in order to bid for government tenders. Hence, most of the government tender information available online is in the local language, Bahasa Malaysia. The Malaysian government is actively promoting local manufacturing of generic drugs and medical devices. There are instances of government procurement favoring locally produced and manufactured drugs, products and equipment— even when the bidding foreign companies’ pricing is far lower, and the products and equipment are of equal or superior quality. see more at www.drugdu.com https://medicaldeviceandequipmentinformation.wordpress.com/2018/02/11/medical-device-products-market-in-malysia/
  13. The future of lung function tests for COPD

    The future of lung function tests for COPD With the global increase of lung diseases such as asthma, severe bronchitis and emphysema, lung function tests are becoming a bigger concern for many people. Spirometry (measuring lung function) is the most well know pulmonary function testand vital to diagnose COPD. Some of the diseases which can be detected are: 1. Chronic obstructive pulmonary disease (COPD) – main term used to describe lung diseases such as asthma, emphysema, chronic bronchitis etc. 2. Asthma – common and long-term lung disease characterised by coughing, shortness of breath or wheezing. 3. Chronic bronchitis – bronchial tubes become inflamed and produce an excessive amount of mucus. 4. Emphysema – long-term progressive disease where alveoli in the lungs become inflamed causing shortness of breath. 5. Cystic fibrosis – genetic lung disease characterised by frequent lung infections and coughing up mucus as a result of this. 6. Pulmonary fibrosis - interstitial lungdiseases resulting in the scarring of the lungs. Doing the test itself is quiet simple and usually involves the patient blowing as hard as possible into a tube which is attached to a spirometer, the main piece of medical equipment used for the test. The results of this lung function test will indicate how healthy the patient’s lungs are. Pulmonary function monitoring is however, becoming just as simple as taking blood pressure and not necessarily something you have to go to the hospital for anymore. With advances in the field, the big clunky machines of the past have been transformed to, smaller, portable medical devices that are simple to use and have great technological features. One example of this is Shenzhen Mellow Hope’s Smart Spirometer which can be used in clinics and homes alike. Not only can you connect this device with your smart phone, it also has a cloud based mobile app platform, allowing patients the possibility of self-monitoring and, with the community forum, patients are capable of keeping track of their health with ease while keeping relevant parties informed. With pulmonary function monitoring in the palm of our hands, lung diseases can now be managed with more precision than ever before. see more at www.drugdu.com source:http://forums.delphiforums.com/medicaldevice/messages/33/1
  14. Have you made your schedule for 2018? Take some time to consider your options and see what Ddu has planned this February! Arab Health Exhibition 2018 Time February 5- 8, 2018 Location Dubai International Convention & Exhibition Centre Brief Introduction The Arab Health Exhibition & Congress is the largest event of its kind in the Middle East. Arab Health provides an unrivalled platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community from the Middle East and beyond. Exhibits 1. Laboratory equipment: testing and analysis equipment, diagnostic equipment, reagents and supplies, medical dressings and sanitary materials etc. 2. Biochemical exhibits: biochemical instruments, bio-pharmaceutical instruments, pharmaceuticals and diagnostics, protein / phthalocyanine synthesis system, cleaning equipment and other consumables. 3. Analytical equipment: electronic and optical microscopes, electronic probes, optical and analyticalequipment. Number of Estimated Attendees 600+ suppliers and 25, 000+ professional visitors MD&M WEST 2018 Time February 6-8, 2018 Location Anaheim Convention Center, Anaheim, California, USA Brief Introduction You'll find the largest showcase of medtech suppliers in the country, plus a full spectrum of solutions across the advanced design and manufacturing supply chain, at the MD&M West expo. Whether you're interested in new materials, intelligent sensors, testing solutions, components, packaging, or anything else needed to bring your concept to market, you can source from more than 2,000 cutting-edge suppliers in a time-saving format. Free presentations, interactive events, and fun activities throughout the expo make this a can't-miss event. Exhibits Disposable medical supplies, therapeutic apparatus and accessories, testing and diagnostic equipment and accessories, electronic medical equipment, medical furniture, laboratory supplies, X-ray CT medical devices and equipment products, auxiliary products for the disables, care and rehabilitation equipment, monitoring equipment, medical packaging materials , ophthalmic equipment, dental equipment, minimally invasive medical imaging products, medical packaging, biochemical products, home care products, medical cutting instruments etc. Number of Estimated Attendees 2,000+ suppliers and 20, 000+ professional visitors Medical Japan 2018 Time Feb. 21 - 23, 2018 Location INTEX Osaka Brief Introduction MEDICAL JAPAN, consisting of 7 specialised shows, is Japan’s largest trade show which covers all the products/ services/ technologies for healthcare, clinical testing, diagnostics and medicine. With great support from The Ministry of Health, Labour and Welfare in Japan, MEDICAL JAPAN is attracting attention. Exhibits 1. Medical Devices and Supplies: medical device products, hospital supply centers, medical imaging, IVD, etc. 2. Nursing and care supplies, medical and health materials, disposable medical supplies, etc. 3. Pharmaceutical production equipment, medical supplies packaging machines, medical containers, pharmaceutical ingredients 4. Hospital IT system, wearable medical device and equipment, telemedicine, etc. 5. Medical device accessories, raw materials of medical devices, medical catheters, filters, syringe pumps. Number of Estimated Attendees 1,200+ suppliers and 38, 000+ professional visitors see more at www.drugdu.com Source: http://forums.delphiforums.com/medicaldevice/messages/32/1
  15. Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain. There is an increasing number of people with irregular diets due to the accelerated pace of modern life. Thus, more and more people suffer from peptic ulcer diseases, stimulating the need for peptic ulcer drugs. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will be sharingChina’s Import and Export Report of Peptic Ulcer Drugs with you. I. Global situation of peptic ulcer drugs market The sales of peptic ulcer drugs account for the biggest part of digestive system drugs and according to the classification of the European Pharmaceutical Research Market Association, they can be divided into the following 5 categories: Proton Pump Inhibitor H2-antagonists Bismuth Preparations Prostaglandins Others According to IMS statistics, the global market of peptic ulcer drugs in 2016 was 20.83 billion USD. The market share of the main products are shown in the following chart. Source: IMS PPI became the main treatment for ulcers due to its fast-acting, long-lasting effects and good acid suppression. The global proton pump inhibitor (PPI) market was 18.146 billion USD in 2016, accounting for 87.2% of the global market for peptic ulcer drugs. In addition to this, omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole were the leading products in peptic ulcer drugs market. Source: PDB, CNKI Currently, the key markets for peptic ulcer drugs are Europe, North America and Asia. The Chinese market ranked first amongst the Asian markets with 1.125 billion USD. The chart below indicates the markets for other regions. Source: PDB, CNKI II. Chinese peptic ulcer drugs market Different from those in global markets, peptic ulcer drugs in the Chinese market are mainly divided into the following categories: Proton Pump Inhibitors H2-antagonists Mucosal Protective Agents Others According to the statistics of PDB, the Chinese peptic ulcer drugs market is growing year by year with a market size exceeding 7.43 billion RMB in 2016 and is expected to reach 8 billion RMB in 2017. 2014-2017 Growth . of Global Market of Anti-Peptic Ulcer Drugs (100 Million RMB) Proton pump inhibitors (PPI) accounted for 91.8% of the Chinese peptic ulcer drugs market H2-antagonists 4.3%, Mucosal Protective Agents 2.1% and others 1.8%. As indicated on the chart below, PPIs dominate the market followed by omeprazole for injection (45%), pantoprazole for injection (37%), lansoprazole for injection (12%) and esomeprazole for injection (6%). Source: PDB According to the statistics of PDB, public hospitals in major cities in China spent 4.5 billion RMB on PPIs in 2016, an increase of 6% over the previous year. Lansoprazole ranked first with market sales of 1.239 billion RMB, an increase of 5.52 %. III. China’s imports of peptic ulcer drugs Domestically manufacture generic drugs are taking the place of imported peptic ulcer drugs. Thus, imported peptic ulcer drugs only accounted for 16.7% of the peptic ulcer drugs market with a total import of 1.24 billion RMB. China mainly imported esomeprazole, omeprazole and hydrotalcite from AstraZeneca and Bayer. PPI esomeprazole (Nexium) from AstraZeneca took up a comparatively big share of China’s imported pharmaceutical drugs. The chart below indicates China’s peptic ulcer drug imports of 2016. Source: PDB IV. China’s export of peptic ulcer drugs With the encouragement of the national industrial policy and the support of technological developments, China’s export market of peptic ulcer drugs is developing rapidly with growing exports. According to the statistics of China custom, exports of pantoprazole sodium and omeprazole are as follows: Source: China Custom V. Chinese leading peptic ulcer drugcompanies Cisen Pharmaceutical Co., Ltd Cisen Pharmaceutical Co., Ltd is a comprehensive chemical manufacturing enterprise in China, one of the top 100 Chinese pharmaceutical industry companies and a national high-tech company. Representative product: Pantoprazole sodium enteric-coated tablets, omeprazole for injection, omeprazole enteric-coated tablets and Lansoprazole tablets Indications: Duodenal ulcer and gastric ulcer Main exporting regions: Pakistan, Angola, Venezuela, Nicaragua and others Jiangsu Aosaikang pharmaceutical Co., Ltd Jiangsu Aosaikang pharmaceutical Co., Ltd is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with manufacturing, marketing promotions and sales of proprietary pharmaceuticals, fine chemicals and health care products. Representative product: Omeprazole sodium for injection and lansoprazole for injection Indications: Peptic ulcer and hemorrhage Main exporting regions: USA Youcare Pharmaceutical Group Co., Ltd. Youcare Pharmaceutical Group Co., Ltd. is involved in drug research and development, pharmaceutical manufacturing, distribution and sales, and foreign trade as one of the private pharmaceutical enterprise groups. Representative product: Omeprazole enteric-coated capsules Indications: Gastric ulcer and duodenal ulcer Main exporting regions: More than 40 countries and regions such as Russia, Pakistan, Germany, Africa, Latin America VI. There is a great potential market for pantoprazole Due to social development, environmental changes, population structures and people's lifestyles, the incidence of peptic ulcers caused by smoking, drinking, emotional stress and drug stimulation is getting higher and higher. In China and around the world, the number of patients with peptic ulcer disease is rapidly increasing. Thus, prevention and treatment of peptic ulcer disease has become an urgent matter. Ddu, the leading global pharmaceutical & medical device B2B online platform, believes that pantoprazole, as a new generation of proton pump inhibitors, is more stable than that of mono alkoxyl pyridine and has better selective effect on parietal cells. Moreover, compared with omeprazole and lansoprazole, pantoprazole is safer and more effective when used in combination with other drugs and has good anti-acid secretion effects. Therefore, pantoprazole is a highly selective H+,K+-ATP enzyme inhibitor with good curative effects and minimal side effect. For more information, please visit http://cn.media.drugdu.com/ source: https://medicaldeviceproducts.quora.com/Ddu-College-China-s-Import-and-Export-Report-of-Peptic-Ulcer-Drugs
×